Table Ib:
Baseline Characteristics in Adults by BMI classification
| BMI classification | |||||
|---|---|---|---|---|---|
| Total (n=1287) | Lean <24 (n=364) | Overweight 25-29 (n=363) | Obese ≥30 (n=560) | p-value | |
| Age (yrs) | 39.8 (13.7) | 34.5 (13.6) | 41.7 (13.8) | 42.0 (12.7) | <0.001 |
| Female, n (%) | 873 (67.8%) | 245 (67.3%) | 197 (54.3%) | 431 (77.0%) | <0.001 |
| Hispanic/Latino, n (%) | 162 (12.6%) | 31 (8.5%) | 53 (14.6%) | 78 (14.0%) | 0.02 |
| Race, n (%) | <0.001 | ||||
| Caucasian | 743 (57.8%) | 254 (69.8%) | 224 (61.7%) | 265 (47.4%) | |
| African-American | 439 (34.1%) | 76 (20.9%) | 102 (28.1%) | 261 (46.7%) | |
| Asian | 33 (2.6%) | 17 (4.7%) | 11 (3.0%) | 5 (0.9%) | |
| Other | 71 (5.5%) | 17 (4.7%) | 26 (7.2%) | 28 (5.0%) | |
| Age of asthma onset (yrs) | 15.9 (15.0) | 13.1 (13.2) | 16.1 (15.2) | 17.6 (15.7) | 0.001 |
| Atopy, n (%) | 897 (69.7%) | 260 (71.4%) | 254 (70.0%) | 383 (68.4%) | 0.61 |
| URI trigger, n (%) | 732 (82.6%) | 173 (84.8%) | 202 (81.8%) | 357 (82.1%) | 0.84 |
| Steroid courses in last yr | 0.6 (1.0) | 0.4 (0.8) | 0.5 (1.0) | 0.7 (1.2) | <0.001 |
| Controller therapy, n (%) | |||||
| Inhaled corticosteroid | 267 (20.8%) | 73 (20.1%) | 83 (22.9%) | 111 (19.8%) | 0.49 |
| Inhaled combo | 837 (65.1%) | 202 (55.5%) | 237 (65.5%) | 398 (71.1%) | <0.001 |
| Oral anti-leukotriene | 277 (21.5%) | 74 (20.3%) | 76 (21.0%) | 127 (22.7%) | 0.67 |
| Pre-Bronchodilator | |||||
| FVC (L) | 3.780 (1.1) | 4.096 (1.0) | 3.982 (1.1) | 3.443 (1.0) | <0.001 |
| FEV1 (L) | 2.787 (0.8) | 3.067 (0.8) | 2.879 (0.9) | 2.546 (0.7) | <0.001 |
| FEV1/FVC (L) | 0.770 (0.1) | 0.792 (0.1) | 0.754 (0.1) | 0.765 (0.1) | <0.001 |
| FEV1 % predicted | 86.4 (14.4) | 89.8 (13.3) | 85.9 (14.8) | 84.5 (14.4) | <0.001 |
| % change in FEV1 | 6.6 (8.2) | 7.4 (7.9) | 7.0 (7.5) | 5.9 (8.7) | 0.02 |
| Asthma Scales | |||||
| ACT | 18.7 (4.6) | 19.3 (4.2) | 18.7 (4.7) | 18.4 (4.8) | 0.16 |
| ACQ | 0.7 (0.373) | 0.721 (0.391) | 0.711 (0.358) | 0.750 (0.365) | 0.68 |
| ASUI | 0.847 (0.149) | 0.862 (0.122) | 0.849 (0.156) | 0.835 (0.159) | 0.14 |
| GERD, n (%) | 318 (24.7%) | 46 (12.6%) | 90 (24.9%) | 182 (32.6%) | <0.001 |
| Regular PPI use, n (%) | 77 (14.5%) | 8 (6.7%) | 14 (9.3%) | 55 (21.2%) | <0.001 |
| OSA, n (%) | 31 (8.7%) | 2 (2.4%) | 5 (5.2%) | 24 (13.6%) | 0.004 |
| Diabetes Mellitus, n (%) | 43 (4.9%) | 0 (0.0%) | 6 (2.4%) | 37 (8.5%) | <0.001 |
| Immunodeficiency, n (%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Smokins, n (%) | 0.054 | ||||
| Current/Former | 236 (18.3%) | 61 (16.8%) | 56 (15.4%) | 119 (21.3%) | |
| Never | 1051 (81.7%) | 303 (83.2%) | 307 (84.6%) | 441 (78.8%) | |
| SHS, n (%) | 437 (34.0%) | 104 (28.6%) | 115 (31.7%) | 218 (38.9%) | 0.003 |
URI – upper respiratory infection; FVC – forced vital capacity; FEV1 – forced expiratory volume in one second; ACT – Asthma Control Test; ACQ – Asthma Control Questionnaire; ASUI – Asthma Symptom Utility Index; GERD – Gastroesophageal reflux disease; PPI – proton pump inhibitor; OSA – obstructive sleep apnea, SHS – secondhand smoke. Bold indicates statistical significance (p<0.05). Results are expressed as number of participants (percentage) for categorical variables and mean (standard deviation) for continuous variables. P-values determined by chi-square test for categorical variableps and Kruskal-Wallis for continuous variables.